The comparison of PAP smear test results of women according to anti mullerian hormone levels

Year 2023, Volume: 40 Issue: 2, 244 - 247, 19.07.2023

İnci Öz , Asena Ayar Madenli , Ergül Demirçivi

Abstract

Aim: This study aims to investigate the relationship between PAP smear test results and anti mullerian hormone (AMH) levels. The PAP smear test is used to screen for cervical cancer. This test identifies malignant or pre-malignant cells of the cervix and permits timely diagnosis and treatment.
Material and Method: This retrospective cross-sectional study included 104 women of reproductive age who applied for a PAP smear test. This study was conducted between October 2019 and December 2020. Patients were clustered as subjects: 1) with an AMH <1ng/ml 2) with an 13ng/ml.
Results: The mean age of the study group was 28.45 ± 3.31 years. There was a statistically significant association between AMH levels and PAP smear test results (p<0.05). AMH>3ng/ml group had a significant relationship with the AGUS PAP smear results. There was a statistically significant association between AMH between 1 and 3 and normal PAP smear test result.
Conclusion: In conclusion, the results indicated that the serum AMH level and PAP smear test results had a significant relationship.

Keywords

Cervical cancer, anti mullerian hormone, pap smear test

References

• 1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-49.
• 2. Agadayi E, Karademir D, Karahan S. Knowledge, Attitudes and Behaviors of Women who have or have not had human papillomavirus vaccine in Turkey about the Virus and the vaccine. J Community Health 2022; 47: 650-7.
• 3. Tanaka S, Palmer M, Katanoda K. Trends in cervical cancer incidence and mortality of young and middle adults in Japan. Cancer Sci 2022; 113: 1801-7.
• 4. Brisson M, Kim JJ, Canfell K, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet 2020; 395: 575-90.
• 5. Marashi T, Irandoost SF, Yoosefi Lebni J, Soofizad G. Exploring the barriers to Pap smear test in Iranian women: a qualitative study. BMC Womens Health 2021; 21: 287.
• 6. Fallahi A, Taymoori P, Aslibeigi F, Khoshravesh S. The Pap Smear Test Experience of Iranian Women: A Qualitative Study. JECH 2022; 8: 291-7.
• 7. Yurci A, Gungor N. Low Antimullerian Hormone Levels Improve Fertility Outcome in Patients with Polycystic Ovary Syndrome. Gynecol Reprod Health 2021; 5: 1-5.
• 8. Rey R, Lukas-Croisier C, Lasala C, Bedecarrás P. AMH/MIS: what we know already about the gene, the protein and its regulation. Mol Cell Endocrinol 2003; 211: 21-31.
• 9. Bedenk J, Vrtačnik-Bokal E, Virant-Klun I. The role of anti-Müllerian hormone (AMH) in ovarian disease and infertility. J Assist Reprod Genet 2020; 37: 89-100.
• 10. Güngör ND, Gürbüz T. Prediction of the number of oocytes based on AMH and FSH levels in IVF candidates. J Surg Med 2020; 4: 733-7.
• 11. Gungor ND, Gurbuz T. Pregnancy Outcomes of Intrauterine Insemination in Age-Matched Young Women According to Serum Anti-Mullerian Hormone Levels. JRM 2021; 66: 195-202.
• 12. Tal R, Seifer CM, Khanimov M, Seifer DB, Tal O. High serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology. Reprod Biol Endocrinol 2020; 18: 20.
• 13. Gürbüz T, Gungor ND, Tanrıdan Okçu N,Alanya Tosun Ş. Correlation Between Antı-Mullerian Hormone Levels And Sexual Dysfunction in Infertile Women. ARJGO 2020; 4: 10-6.
• 14. Gungor ND, Gurbuz T, Onal M. Comparison of complication rates after transvaginal ultrasound-guided oocyte pick-up procedures with respect to ovarian response. Clin Exp Reprod Med 2022; 49: 142-8.
• 15. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 2009; 41: 1149-60.
• 16. Oh SR, Choe SY, Cho YJ. Clinical application of serum anti-Müllerian hormone in women. Clin Exp Reprod Med 2019; 46: 50-9.
• 17. Cascardi E, Cazzato G, Daniele A, et al. Association between Cervical Microbiota and HPV: Could This Be the Key to Complete Cervical Cancer Eradication? Biology (Basel) 2022; 11: 1114.
• 18. Gupta S, Gupta MK. Computational prediction of cervical cancer diagnosis using ensemble-based classification algorithm. The Computer Journal. 2022; 65: 1527-39.
• 19. Marconi C, Duarte MT, Silva DC, Silva MG. Prevalence of and risk factors for bacterial vaginosis among women of reproductive age attending cervical screening in southeastern Brazil. Int J Gynaecol Obstet 2015; 131: 137-41. .
• 20. Bautista CT, Wurapa E, Sateren WB, Morris S, Hollingsworth B, Sanchez JL. Bacterial vaginosis: a synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections. Mil Med Res 2016; 3: 4.
• 21. Teixeira PM, Vital WC, Lima AA, et al. Bacterial vaginosis: prevalence, risk profile and association with sexually transmitted infections. REDALYC 2020;10(3).
• 22. Sachan PL, Singh M, Patel ML, Sachan R. A Study on Cervical Cancer Screening Using Pap Smear Test and Clinical Correlation. Asia Pac J Oncol Nurs 2018; 5: 337-41.
• 23. Sharif YH. Clinical correlation of cervical cancer screening using Pap smear test. J Popul Ther Clin Pharmacol 2022; 29: 1-8.
• 24. Ghosh S, Pattanshetty SM, Mallya SD, et al. Cervical cytology and associated factors among tribal women of Karnataka, India. PLoS One 2021; 16: e0248963.